Maizar Diskus

Fluticasone propionate and Salmeterol, the active ingredients in Maizar Diskus, are an inhaled corticosteroid/long‑acting β2‑agonist combination presented as a dry powder inhaler for inhalation use. It provides maintenance therapy for asthma and chronic obstructive pulmonary disease in adult patients.

GNH USA supplies Maizar Diskus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable logistics for global distribution.

Maizar Diskus, an inhaled corticosteroid/long‑acting β2‑agonist (ICS/LABA) combination, is indicated for maintenance therapy of obstructive airway diseases.

- Asthma: improves symptom control and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): enhances lung function and decreases symptom burden. - Patients requiring combination therapy: provides both anti‑inflammatory and bronchodilator effects when a single inhaled corticosteroid is insufficient.

The most frequently reported adverse reactions with Maizar Diskus involve the respiratory tract and local irritation, while rare events may affect systemic systems.

Common Side Effects: - Throat irritation: discomfort or soreness in the throat after inhalation. - Hoarseness: voice changes due to local steroid effect. - Oral candidiasis: fungal infection of the mouth. - Cough: transient coughing post‑dose. - Headache: mild to moderate headache. - Nasopharyngitis: inflammation of nasal passages and throat.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Adrenal suppression: reduced cortisol production with prolonged use. - Severe allergic reaction: anaphylaxis or angioedema. - Pneumonia: especially in COPD patients. - Cardiac arrhythmia: irregular heart rhythm. - Immune system effects: increased susceptibility to infections.

Before prescribing Maizar Diskus, clinicians should consider several safety measures to minimise risks.

- Assess disease severity: evaluate asthma or COPD control prior to initiation. - Monitor oral health: inspect for thrush and advise rinsing mouth after each use. - Ensure proper inhalation technique: train patients on correct DPI usage. - Avoid abrupt discontinuation: taper if long‑term therapy is stopped. - Caution in cardiovascular disease: evaluate risk of β2‑agonist effects on heart rate and blood pressure. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Maizar Diskus may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase systemic steroid exposure. - Non‑selective β‑blockers (e.g., propranolol): can diminish bronchodilator response and precipitate bronchospasm.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug levels and reduce effectiveness. - Other sympathomimetics (e.g., pseudoephedrine): may enhance cardiovascular side effects. - Diuretics (e.g., furosemide): can increase risk of hypokalaemia when combined with β2‑agonists.